BCLI - BRAINSTORM CELL THERAPEUTICS INC.

0.84
-0.330   -39.286%

Share volume: 819,677
Last Updated: 07-18-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$1.17
-0.33
-0.28%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 25%
Liquidity 37%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
-46.84%
2 Year
141.24%
Key data
Stock price
$0.84
P/E Ratio 
0.00
DAY RANGE
$0.59 - $0.89
EPS 
-$1.49
52 WEEK RANGE
$0.59 - $1.92
52 WEEK CHANGE
-$47.17
MARKET CAP 
7.342 M
YIELD 
N/A
SHARES OUTSTANDING 
11.035 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-13-2025
BETA 
2.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Chaim Lebovits
Region: US
Website: brainstorm-cell.com
Employees: 40
IPO year: 2011
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Brainstorm Cell Therapeutics Inc. engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. It is developing NurOwn, which has completed Phase III clinical trial for the. treatment of amyotrophic lateral sclerosis; and Phase II clinical trial. for. progressive multiple sclerosis and alzheimer's disease. The company was formerly known as Golden Hand Resources Inc.

Recent news